Kintor Pharma-B (09939) Announces KT-939 Receives Notification of Invention Patent Grant

Stock News10-21

Kintor Pharma-B (09939) has issued an announcement that on October 21, 2026, the group received a notification of invention patent grant from the China National Intellectual Property Administration (CNIPA) for its independently developed novel high-efficiency tyrosinase inhibitor KT-939 (Chinese trade name: OXIMIDOL®KT-939, English trade name: OXIMIDOL®KT-939), which is designed to inhibit melanin production.

The patent relates to a tyrosinase inhibitor and its uses (application number: 202580002670.3). It was submitted by the company's wholly-owned subsidiary, Suzhou Kintor Pharmaceuticals Co., Ltd., with a prioritized examination request filed on March 27, 2026, and was granted prioritized examination status by CNIPA on June 12, 2026. From the submission of the prioritized examination request to the issuance of the notification of invention patent grant, the process took approximately six months. The company is currently completing the subsequent authorization registration procedures in accordance with applicable laws.

According to the claims text proposed for grant, the specific chemical structure of KT-939 (Chinese trade name: OXIMIDOL®KT-939, English trade name: OXIMIDOL®KT-939) is covered by both the specific compound claims and the compound generic formula claims of the patent application, and falls within the scope of protection of the patent application, making it a subject of the proposed protection.

KT-939 is a core commercialized product of the company. The grant of the invention patent for KT-939 in China is expected to help strengthen KT-939's competitive advantage in the high-end cosmetic ingredient market for whitening and spot-removing products. The company submitted all registration application materials for KT-939 as an efficacy cosmetic ingredient to the National Medical Products Administration (NMPA) on September 18, 2026, and will strive to obtain NMPA approval as soon as possible. In addition, the company is developing analogs of KT-939 as topical innovative drugs for the treatment of pigmentation-related disorders such as melasma.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment